GlassScriptPhysician profile
Teri L Harrison
NPI 1124414966
$1,126.83
in general payments reported to CMS, 2019-2025
19 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $42.25 · 2023: $139 · 2024: $330 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $30.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.02 |
| Education | $30.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $201.83 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $165.16 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $95.52 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $91.08 | 2021 | |
| Glaxosmithkline, LLC. | $82.21 | 2021-2025 | Trelegy Ellipta |
| Abbvie INC. | $79.77 | 2021-2025 | |
| Pfizer INC. | $75.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $72.05 | 2021-2024 | Rexulti |
| Alkermes, INC. | $56.15 | 2023 | Vivitrol |
| Indivior INC. | $37.64 | 2025 | Sublocade |
| Organon LLC | $31.00 | 2022-2025 | Nexplanon |
| Axsome Therapeutics, INC. | $28.82 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $18.88 | 2021 | |
| Orexo US, INC. | $18.51 | 2025 | Zubsolv |
| Merck Sharp & Dohme LLC | $16.63 | 2023 | Dificid, Pifeltro, Delstrigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2021 | |
| Neurocrine Biosciences, INC. | $15.20 | 2023 | Ingrezza |
| Lilly USA, LLC | $13.02 | 2021 | |
| Amgen INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.